Insider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells $2,655,900.00 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 30,000 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the transaction, the chief executive officer owned 324,879 shares in the company, valued at approximately $28,761,537.87. The trade was a 8.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

James Richard Porter also recently made the following trade(s):

• On Monday, May 4th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $101.69, for a total value of $3,050,700.00.
• On Monday, April 6th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $103.77, for a total transaction of $3,113,100.00.

Nuvalent Price Performance

NASDAQ:NUVL opened at $123.25 on Friday. Nuvalent, Inc. has a one year low of $71.13 and a one year high of $123.62. The company has a market cap of $9.74 billion, a P/E ratio of -20.34 and a beta of 1.15. The firm’s fifty day moving average price is $104.21 and its two-hundred day moving average price is $103.45.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the business posted ($1.18) EPS. As a group, equities research analysts expect that Nuvalent, Inc. will post -5.74 earnings per share for the current year.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently modified their holdings of NUVL. AQR Capital Management LLC lifted its holdings in shares of Nuvalent by 64.8% during the first quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock worth $700,000 after buying an additional 3,881 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock worth $32,171,000 after buying an additional 159,873 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Nuvalent by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock worth $10,634,000 after buying an additional 12,123 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Nuvalent by 28.7% during the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock worth $1,366,000 after buying an additional 4,293 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Nuvalent during the second quarter worth $412,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s purchase underscores strong strategic demand for Nuvalent’s oncology assets, especially its selective tyrosine kinase inhibitor programs, which supports the view that the company’s pipeline has major pharma value. Reuters article on GSK deal
• Positive Sentiment: Market commentary and analyst coverage suggest the acquisition is strategically important for GSK’s oncology rebuild, reinforcing confidence that the transaction is meaningful and likely to close. Reuters article on GSK oncology rebuild
• Neutral Sentiment: Several analyst downgrades followed the takeover announcement, but their revised price targets remain close to the deal price, so the impact on the stock appears limited. Analyst downgrade coverage
• Neutral Sentiment: Law firms have begun reviewing whether the sale process and price were fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly weigh on sentiment by suggesting insiders have been reducing exposure ahead of the transaction. SEC insider filing

Analyst Ratings Changes

Several equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Stifel Nicolaus set a $124.00 price objective on shares of Nuvalent in a report on Tuesday. Raymond James Financial downgraded shares of Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Leerink Partners set a $165.00 price objective on shares of Nuvalent in a report on Wednesday, June 3rd. Finally, Truist Financial set a $124.00 target price on Nuvalent in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $131.15.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.